JP2016539629A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539629A5
JP2016539629A5 JP2016524423A JP2016524423A JP2016539629A5 JP 2016539629 A5 JP2016539629 A5 JP 2016539629A5 JP 2016524423 A JP2016524423 A JP 2016524423A JP 2016524423 A JP2016524423 A JP 2016524423A JP 2016539629 A5 JP2016539629 A5 JP 2016539629A5
Authority
JP
Japan
Prior art keywords
vector
ltr
vector according
optional
retroviral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016524423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539629A (ja
JP6525986B2 (ja
Filing date
Publication date
Priority claimed from GBGB1318347.0A external-priority patent/GB201318347D0/en
Application filed filed Critical
Publication of JP2016539629A publication Critical patent/JP2016539629A/ja
Publication of JP2016539629A5 publication Critical patent/JP2016539629A5/ja
Application granted granted Critical
Publication of JP6525986B2 publication Critical patent/JP6525986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016524423A 2013-10-16 2014-10-16 レトロウイルスベクター Active JP6525986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1318347.0 2013-10-16
GBGB1318347.0A GB201318347D0 (en) 2013-10-16 2013-10-16 Retroviral vectors
PCT/GB2014/053102 WO2015056014A1 (en) 2013-10-16 2014-10-16 Retroviral vectors

Publications (3)

Publication Number Publication Date
JP2016539629A JP2016539629A (ja) 2016-12-22
JP2016539629A5 true JP2016539629A5 (enExample) 2017-11-24
JP6525986B2 JP6525986B2 (ja) 2019-06-05

Family

ID=49680159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524423A Active JP6525986B2 (ja) 2013-10-16 2014-10-16 レトロウイルスベクター

Country Status (7)

Country Link
US (1) US10184136B2 (enExample)
EP (1) EP3058076B1 (enExample)
JP (1) JP6525986B2 (enExample)
CN (1) CN105705645B (enExample)
ES (1) ES2759049T3 (enExample)
GB (1) GB201318347D0 (enExample)
WO (1) WO2015056014A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
KR102673203B1 (ko) 2016-04-20 2024-06-10 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. Pklr의 유전자 발현 증강을 위한 조성물 및 방법
IL320371A (en) * 2016-09-08 2025-06-01 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Gene therapy for patients with fanconi anemia
AU2018227583B2 (en) 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
CN110913954A (zh) 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
WO2019040655A1 (en) * 2017-08-22 2019-02-28 The Regents Of The University Of California LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES
AU2018352583B2 (en) 2017-10-16 2025-04-17 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. Lentiviral vectors for delivery of PKLR to treat Pyruvate Kinase Deficiency
US12539316B2 (en) 2018-04-11 2026-02-03 Spacecraft Seven, Llc Compositions and methods for stem cell transplant
IL278213B2 (en) 2018-04-27 2026-04-01 Rocket Pharmaceuticals Ltd A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
CN108676815A (zh) * 2018-05-31 2018-10-19 深圳市免疫基因治疗研究院 一种b型血友病慢病毒载体、慢病毒及其制备方法和应用
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
IL280465B2 (en) 2018-07-30 2025-03-01 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Methods for gene modification of hematopoietic cells
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
BR112021017744A2 (pt) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CA3140668A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2022032226A1 (en) 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
GB202019084D0 (en) * 2020-12-03 2021-01-20 Ucl Business Ltd Retroviral vectors
CA3209115A1 (en) * 2021-01-25 2022-07-28 Prevail Therapeutics, Inc. Modulation of aav-based gene expression
KR20240051112A (ko) 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
CN114931652B (zh) * 2022-06-23 2024-01-26 中国人民解放军陆军军医大学第一附属医院 一种Hmga2基因在修复受损视网膜中的应用
US20250375524A1 (en) 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
GB202306491D0 (en) 2023-05-03 2023-06-14 Ucl Business Ltd Retroviral vectors
CN120738286B (zh) * 2025-07-03 2026-06-30 北京石油化工学院 过表达Bag6的CHO细胞株在制备提升外源重组蛋白表达量中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707091B1 (fr) * 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
US5714353A (en) * 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
FR2751345B1 (fr) 1996-07-16 1998-09-18 Univ Paris Curie Lignees d'encapsidation hautement productrices
US20050266544A1 (en) 1999-04-30 2005-12-01 Human Gene Therapy Research Institute Methods and compositions for increasing viral vector production in packaging cell lines
US8158413B2 (en) * 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
JP2007054069A (ja) * 2005-08-24 2007-03-08 Medizinische Hochschule Hannover 自己不活性化レトロウイルスベクター
CN102443604B (zh) * 2011-11-25 2014-12-31 上海市儿童医院 一种安全性慢病毒载体及其应用

Similar Documents

Publication Publication Date Title
JP2018513681A5 (enExample)
JP2011505835A5 (enExample)
FI3546585T3 (fi) Muokatun intronin käsittäviä nukleiinihappoja käytettäviksi hyperbilirubinemian hoidossa
JP2016521554A5 (enExample)
RU2018122636A (ru) Стабильные клеточные линии для продуцирования ретровирусов
JP2015096070A5 (enExample)
JP2016528919A5 (enExample)
MX2021015157A (es) Construcciones de edicion de genes dirigidas y metodos de uso de las mismas.
JP2016528918A5 (enExample)
JP2016528916A5 (enExample)
JP7176756B2 (ja) パーキンソン病を処置するためのウイルスベクター
JP2017505117A5 (enExample)
JP2017532302A5 (enExample)
JP2017509350A5 (enExample)
JP2018534937A5 (enExample)
JP2013509168A5 (enExample)
EP4600366A3 (en) Cas 9 retroviral integrase systems for targeted incorporation of a dna sequence into a genome of a cell
EA201692361A1 (ru) Лентивирусные векторы
JP2017538401A5 (enExample)
JP2011004755A5 (enExample)
JP2016501531A5 (enExample)
JP2008545406A5 (enExample)
WO2015158749A3 (de) Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark
RU2016101246A (ru) Направленная интеграция
JP2018522595A5 (enExample)